The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) hit a new 52-week low and has $41.49 target or 6.00% below today’s $44.14 share price. The 5 months bearish chart indicates high risk for the $45.80B company. The 1-year low was reported on Oct, 13 by Barchart.com. If the $41.49 price target is reached, the company will be worth $2.75B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 866,789 shares traded hands. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 23.90% since March 10, 2016 and is downtrending. It has underperformed by 31.42% the S&P500.
Analysts await Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to report earnings on November, 3. They expect $1.30 EPS, down 3.70% or $0.05 from last year’s $1.35 per share. TEVA’s profit will be $1.35 billion for 8.49 P/E if the $1.30 EPS becomes a reality. After $1.25 actual EPS reported by Teva Pharmaceutical Industries Ltd (ADR) for the previous quarter, Wall Street now forecasts 4.00% EPS growth.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Ratings Coverage
Out of 19 analysts covering Teva Pharma (NYSE:TEVA), 15 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 79% are positive. Teva Pharma has been the topic of 28 analyst reports since July 21, 2015 according to StockzIntelligence Inc. As per Thursday, July 14, the company rating was maintained by Jefferies. The firm has “Buy” rating by Citigroup given on Tuesday, July 28. As per Tuesday, July 28, the company rating was maintained by Argus Research. The rating was initiated by Mizuho with “Buy” on Monday, December 7. The company was upgraded on Friday, December 4 by Guggenheim. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Outperform” rating by Wells Fargo on Friday, February 19. The company was reinitiated on Wednesday, July 29 by Morgan Stanley. As per Tuesday, September 29, the company rating was initiated by Nomura. The stock has “Neutral” rating given by Credit Suisse on Wednesday, May 4. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Buy” rating by HSBC on Monday, July 18.
According to Zacks Investment Research, “TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.”
TEVA Company Profile
Teva Pharmaceutical Industries Limited, incorporated on February 13, 1944, is a global pharmaceutical company. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Firm operates through two divisions: Generic medicines and Specialty medicines. The Firm has a global portfolio of approximately 1,000 molecules.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.